Table 1.
Baseline characteristics for the LDL-C analysis set
| Variables | LDL ≤1.4 mmol/L N=1407 |
1.4<LDL≤1.8 mmol/L N=1636 |
1.8<LDL≤2.6 mmol/L N=3655 |
LDL >2.6 mmol/L N=4040 |
P value |
| Women, n (%) | 378 (26.9) | 439 (26.8) | 1057 (28.9) | 1517 (37.6) | <0.001 |
| Mean age, years (SD) | 60.8±11.9 | 62.4±11.3 | 62.2±11.3 | 62.8±11.1 | <0.001 |
| Ethnicity (non-Han), n (%) | 30 (2.1) | 49 (3.0) | 122 (3.3) | 104 (2.6) | 0.07 |
| Current smoker, n (%) | 435 (30.9) | 525 (32.1) | 1239 (33.9) | 1198 (29.7) | <0.001 |
| Heavy drinker, n (%)* | 185 (13.2) | 210 (12.8) | 545 (14.9) | 589 (14.6) | 0.12 |
| Triglycerides (IQR) | 1.3 (0.9–1.9) | 1.3 (1.0–1.8) | 1.3 (1.0–1.8) | 1.5 (1.1–2.0) | <0.001 |
| TC, mmol/L | 2.7 (2.4–3.1) | 3.2 (3.0–3.5) | 3.8 (3.5–4.1) | 4.9 (4.5–5.5) | <0.001 |
| HDL-C, mmol/L | 0.8 (0.7–1.0) | 0.9 (0.8–1.1) | 0.9 (0.8–1.1) | 1.0 (0.8–1.2) | <0.001 |
| LDL-C, mmol/L | 1.2 (1.0–1.3) | 1.6 (1.5–1.7) | 2.2 (2.0–2.4) | 3.2 (2.9–3.8) | <0.001 |
| BMI | 24.4 (22.5–26.4) | 24.5 (22.7–26.6) | 24.4 (22.5–26.4) | 24.5 (22.7–26.7) | 0.06 |
| Systolic pressure, mm Hg | 145.0 (132.5–160.0) | 146.5 (133.0–161.0) | 148.5 (135.0–163.5) | 150.0 (136.0–166.5) | <0.001 |
| Medical history, n (%) | |||||
| Ischaemic stroke | 369 (26.2) | 429 (26.2) | 715 (19.6) | 748 (18.5) | <0.001 |
| TIA | 44 (3.1) | 46 (2.8) | 115 (3.6) | 102 (2.5) | 0.38 |
| Coronary heart diseases | 147 (10.5) | 193 (11.8) | 366 (10.0) | 449 (11.1) | 0.20 |
| Atrial fibrillation | 93 (6.6) | 124 (7.6) | 272 (7.4) | 257 (6.4) | 0.19 |
| Hypertension | 897 (63.8) | 1045 (63.9) | 2295 (62.8) | 2516 (62.3) | 0.62 |
| Diabetes mellitus | 386 (27.4) | 394 (24.1) | 824 (22.5) | 960 (23.8) | 0.004 |
| Hypercholesterolaemia | 119 (8.5) | 120 (7.3) | 302 (8.3) | 341 (8.4) | 0.56 |
| NIHSS at admission, median (IQR) | 3.0 (1.0–6.0) | 3.0 (1.0–6.0) | 3.0 (1.0–6.0) | 3.0 (1.0–6.0) | <0.001 |
| NIHSS 0–3 | 743 (52.8) | 914 (55.9) | 1974 (54.0) | 2073 (51.3) | 0.009 |
| NIHSS ≥4 | 664 (47.2) | 722 (44.1) | 1681 (46.0) | 1967 (48.7) | |
| mRS (IQR) | 0 (0–1.0) | 0 (0–1.0) | 0 (0–1.0) | 0 (0–0) | <0.001 |
| Stroke subtype, n (%) | |||||
| LAA | 303 (21.5) | 390 (23.8) | 933 (25.5) | 1092 (27.0) | 0.0095 |
| CE | 81 (5.8) | 96 (5.9) | 251 (6.9) | 256 (6.3) | |
| SAO | 312 (22.2) | 359 (21.9) | 740 (20.3) | 819 (20.3) | |
| Other | 21 (1.5) | 16 (1.0) | 38 (1.0) | 47 (1.2) | |
| Unknown | 690 (49.0) | 775 (47.4) | 1693 (46.3) | 1826 (45.2) | |
| Prestroke antiplatelet therapy, n (%) | 1357 (97.4) | 1569 (97.1) | 3504 (96.7) | 3894 (97.0) | 0.57 |
| Prestroke LLT, n (%) | 1359 (97.6) | 1558 (96.4) | 3498 (96.5) | 3897 (97.1) | 0.15 |
| Statin, n (%) | 1355 (97.3) | 1556 (96.3) | 3491 (96.3) | 3887 (96.9) | 0.27 |
BMI, body mass index; CE, cardiogenic embolism; HDL-C, high-density lipoprotein cholesterol; LAA, large artery atherosclerosis; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SAO, small artery occlusion; TC, total cholesterol; TIA, transient ischaemic attack.